Case Studies

Learn how Syngene enabled chiral inversion analysis through integrated in vitro and in vivo studies, delivering high-quality data that advanced drug development for a targeted protein degradation program.

Learn how Syngene helped a pharma client optimize extended-release drug development by identifying the right animal species as a preclinical model. This decision enhanced PK study accuracy, reduced development time, and supported regulatory success for a once-daily epilepsy treatment.

Learn how Syngene collaborated with a pharma company to develop the drug substance and drug product for a unique molecule to treat locally advanced lung cancer, including optimizing the process to enable commercial manufacturing of the API.

Learn how Syngene partnered with a global producer of specialty polymers to develop a novel, high-performance polymer for use in sustainable energy generation.

Learn how Syngene scientists scaled up a clone directly from lab scale to clinical scale and enabled clinical batch manufacturing of the product with an improved titer of >5g/L.

Learn how Syngene executed complex preclinical studies, consolidating data across pharmacokinetics, biomarker modulation, and gene expression analysis, and provided comprehensive insights for the client’s development decision on bile acid modulators for paediatric liver disease.

Learn how Syngene’s expertise in process optimization enabled a biopharma company to achieve high product quality and yield for its PPQ batches, including enabling appropriate scale-up to commercial.

Learn how Syngene developed a green synthesis process for a growth promoter drug for an animal health company that reduced the cE factor and PMI value by 80% while achieving high yield and cost-efficiency.

Learn how Syngene’s platform approach to mAb manufacturing helped a biopharma company achieve a four-fold increase in titer in less than a year, resulting in improved efficiency and reduced costs.

Learn how Syngene supported a pharma company in completing IND-enabling safety tox studies for their lead compound for treating painful neuropathies in less than nine months.